BTF3L4

Across TCGA pan-cancer cohorts, BTF3L4 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated BTF3L4 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher BTF3L4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BTF3L4 expression acts as an unfavorable survival marker.

SARC and ACC are the cancer types where BTF3L4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.096	0.611	.005	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

BTF3L4–SARC (DFS)

Open the SARC breakdown →